Trials / Recruiting
RecruitingNCT06814938
A Study of a Novel Precision Medicine Approach For Obesity
A Novel Precision Medicine Approach For Obesity: A Randomized, Multi-Center Trial
- Status
- Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 135 (estimated)
- Sponsor
- Mayo Clinic · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study is being done to assess the efficacy of a saliva- based biomarker to predict response to semaglutide for the treatment of obesity.
Detailed description
The purpose of this study is to test the effectiveness of semaglutide 2.4 mg SQ weekly in patients with obesity with a positive MyPhenome test for abnormal postprandial satiety compared to patients with obesity with a negative MyPhenome test for abnormal postprandial satiety.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Semaglutide | 2.4 mg subcutaneous weekly |
| DRUG | Placebo | Looks exactly like the study drug, but it contains no active ingredient administered subcutaneous weekly |
Timeline
- Start date
- 2025-02-21
- Primary completion
- 2027-12-01
- Completion
- 2028-11-01
- First posted
- 2025-02-07
- Last updated
- 2026-03-02
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06814938. Inclusion in this directory is not an endorsement.